2024-04-27
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
2024-04-08
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
Job Ref: TS-23-003 – Principal Scientist (Personalized Medicine)
Location: Hong Kong
Job Ref: TS-23-05 – Scientist (with a title of Laboratory Manager)
Location: Hong Kong
2023-08-02
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
Job Ref: AR-22-05 – Digital Marketing Assistant
Location: Hong Kong
Our Focus
Our Focus Gastrointestinal Cancers Gastrointestinal cancers presents a pressing challenge marked by unmet medical needs. Stomach, pancreas, colon, bile duct, and liver cancers collectively bear a significant burden, characterized by their high mortality rates and limited treatment alternatives. The complexity of these malignancies demands a new era of innovative therapeutic interventions that can effectively target the intricate molecular pathways driving […]
Management Team
Arbele is founded by scientists and senior executives with vast experience from biotech and pharmaceutical industries, and is supported by highly capable legal, and financial professionals
About Arbele
Arbele’s mission is to create more effective treatments for GI cancers
Social Impact
Our business is to maximize availability of more effective cancer treatments for greater global health